Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02942888 · ClinicalTrials.gov registry record · NA
The Effects of Nicotinamide Adenine Dinucleotide (NAD) on Brain Function and Cognition
A NA study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- NA
- Development phase
- 46
- Enrollment target
NCT02942888 is a NA study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 46 participants.
The verdict
NCT02942888, a NA study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- NA
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effects of Niagen (nicotinamide riboside, vitamin B3), on NAD levels, brain function including cognition and blood flow in people diagnosed with mild cognitive impairment (MCI).
Interventions
- DIETARY_SUPPLEMENT Nicotinamide riboside
- DIETARY_SUPPLEMENT Sugar Pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2017-11-30 |
| Est. Completion | 2021-08-16 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02942888
The ClinicalTrials.gov registry entry for NCT02942888 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nicotinamide riboside is the first listed.
NCT02942888 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02942888 about?
NCT02942888 is a clinical study titled "The Effects of Nicotinamide Adenine Dinucleotide (NAD) on Brain Function and Cognition". The purpose of this study is to determine the effects of Niagen (nicotinamide riboside, vitamin B3), on NAD levels, brain function including cognition and blood flow in people diagnosed with mild cognitive impairment (MCI).
What is the current status of trial NCT02942888?
This trial is currently completed. It is a NA study. The enrollment target is 46 participants. The study started on 2017-11-30. Estimated completion is 2021-08-16.
What interventions are being tested in trial NCT02942888?
The interventions under investigation include: Nicotinamide riboside (DIETARY_SUPPLEMENT), Sugar Pill (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02942888?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.